Evidence against rapid reversal of antiplatelet medications in acute intracerebral hemorrhage
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Volume of intracerebral hemorrhage (ICH) is the most important determinant of outcome after ICH.1,2 In prospective studies, the volume of ICH increases by more than a third in 28–38% of patients with ICH during the first hours after onset and this growth is associated with neurologic deterioration.1,3 Identification of factors that are related to the baseline volume of ICH and subsequent ICH growth can provide insights into the pathophysiology of ICH and can lead to potential therapies designed to limit or stop ICH growth.
The most consistently identified factor associated with ICH growth is the time from symptom onset to baseline CT imaging, which demonstrates the time-dependent nature of ICH growth that is limited in most patients to the first 3–4 hours.1,3,4 Warfarin use is clearly associated with larger volumes of ICH on the baseline CT, subsequent ICH growth, and increased mortality.5,6 The biologic underpinning for this association is straightforward and therapy to reverse the anticoagulant effect of warfarin is part of standard practice in patients with ICH.2 Proposed trials of newer agents to more quickly reverse the …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan